Role of the immune system in hypertension: Modulation by dietary antioxidants

International Journal of Angiology

Volumn 20, Issue 4, 2011, Pages 189-211

  Vasdev, Sudesh ^a   Stuckless, Jennifer ^a   Richardson, Vernon ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

advanced glycation end products; dietary antioxidants; Hypertension; immune system; inflammatory cytokines; insulin resistance; macrophages; oxidative stress; receptors for advanced glycation end products; renal damage; renin angiotensin system; T cells

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; C REACTIVE PROTEIN; CALCIUM; CATECHOLAMINE; CYSTEINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; GAMMA TOCOPHEROL; ICI 8731; INSULIN; ION CHANNEL; LISINOPRIL; METHYLGLYOXAL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PYRIDOXINE; RAS PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TEMPOL; THIOCTIC ACID; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ALLERGIC ENCEPHALOMYELITIS; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CELL INFILTRATION; CLINICAL FEATURE; DAIRY PRODUCT; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESSENTIAL HYPERTENSION; FRUIT; GLUCOSE METABOLISM; HEART DISEASE; HEREDITY; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; LIFESTYLE; LIPID METABOLISM; LOW FAT DIET; MULTIPLE SCLEROSIS; NONHUMAN; NUTRITIONAL REQUIREMENT; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTAKE; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SODIUM RESTRICTION; STROKE; THERAPY EFFECT; TREATMENT DURATION; VASCULAR RESISTANCE; VEGETABLE; VITAMIN INTAKE;

EID: 81755178430     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1288941     Document Type: Review

References (253)

1. World Health Organization. Chronic Disease- key risk factors include high cholesterol, high blood pressure, low fruit and vegetable intake. Available at: http://www.who.int/dietphysicalactivity/publications/facts/riskfactors/en/ Accessed June 9, 2010
2. World Health Organization. Quantifying selected major risks to health. In: World Health Organization. The World Health Report [chapter 4]. Geneva World Health Organization 2002 1-13
3. He J, Whelton P K. Epidemiology and prevention of hypertension. Med Clin North Am 1997 81 5 1077-1097 (Pubitemid 27427956)
4. Klag M J., Whelton P K., Randall B L. et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996 334 1 13-18 (Pubitemid 26012498)
5. Deshmukh R, Smith A, Lilly L S. Hypertension. In: Lilly L S. ed. Pathophysiology of Heart Disease. 2nd ed. Philadelphia Lippincott Williams and Wilkins 1998 267-288
6. Fu M LX. Do immune system changes have a role in hypertension? J Hypertens 1995 13 11 1259-1265 (Pubitemid 26003263)
7. Luft F C., Mervaala E, Müller D N. et al. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension 1999 33 1 Pt 2 212-218 (Pubitemid 29065662)
8. Sesso H D., Buring J E., Rifai N, Blake G J., Gaziano J M., Ridker P M. C-reactive protein and the risk of developing hypertension. JAMA 2003 290 22 2945-2951 (Pubitemid 37505526)
9. Stumpf C, John S, Jukie J et al. Enhanced levels of platelet P-selectin and circulatory cytokines in young patients with mild arterial hypertension. J Hypertens 2005 23 995-1000 (Pubitemid 40637918)
10. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003 21 10 1841-1846 (Pubitemid 37290102)
11. Chae C U., Lee R T., Rifai N, Ridker P M. Blood pressure and inflammation in apparently healthy men. Hypertension 2001 38 3 399-403 (Pubitemid 34225673)
12. Cheng Z J., Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005 11 6 RA194-RA205 (Pubitemid 40904729)
13. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987 317 6 350-357 (Pubitemid 17118813)
14. Reaven G M. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991 90 2A 7S-12S
15. Sagar S, Kallo I J., Kaul N, Ganguly N K., Sharma B K. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992 111 1-2 103-108
16. Kumar K V., Das U N. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993 19 1 59-66 (Pubitemid 23310628)
17. Panza J A., Casino P R., Badar D M., Quyyumi A A. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993 87 5 1475-1481 (Pubitemid 23133090)
18. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998 97 22 2222-2229 (Pubitemid 28265383)
19. Vasdev S, Ford C A., Longerich L, Parai S, Gadag V, Wadhawan S. Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine. Artery 1998 23 1 10-36 (Pubitemid 30045665)
20. Vasdev S, Ford C A., Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens 2000 18 5 567-573 (Pubitemid 30303487)
21. Vasdev S, Ford C A., Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis 2000 10 6 339-346
22. Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: prevention by alpha-lipoic acid supplementation. Mol Cell Biochem 2003 254 1-2 319-326 (Pubitemid 37483768)
23. Vasdev S, Gill V, Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem Biophys 2007 49 1 48-63 (Pubitemid 47415346)
24. Wu L. Is methylglyoxal a causative factor for hypertension development? Can J Physiol Pharmacol 2006 84 1 129-139 (Pubitemid 44011957)
25. Midaoui A E., Elimadi A, Wu L, Haddad P S., de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003 16 3 173-179 (Pubitemid 36293060)
26. Wang X, Desai K, Clausen J T., Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004 66 6 2315-2321 (Pubitemid 41115295)
27. Wang X, Desai K, Chang T, Wu L. Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 2005 23 8 1565-1573 (Pubitemid 41104829)
28. Folli F, Kahn C R., Hansen H, Bouchie J L., Feener E P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997 100 9 2158-2169 (Pubitemid 27500137)
29. Schulman I H., Zhou M S., Raij L. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Curr Hypertens Rep 2005 7 1 61-67 (Pubitemid 40277791)
30. Schmieder R E., Langenfeld M R., Friedrich A, Schobel H P., Gatzka C D., Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996 94 6 1304-1309 (Pubitemid 26307257)
31. Ogihara T, Asano T, Ando K et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002 40 6 872-879 (Pubitemid 35434909)
32. Crowley S D., Gurley S B., Herrera M J. et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006 103 47 17985-17990 (Pubitemid 44852272)
33. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994 94 6 2511-2515 (Pubitemid 24379629)
34. Kahn N N., Acharya K, Bhattacharya S et al. Nitric oxide: the second messenger of insulin. IUBMB Life 2000 49 5 441-450 (Pubitemid 30436180)
35. Montagnani M, Ravichandran L V., Chen H, Esposito D L., Quon M J. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 2002 16 8 1931-1942 (Pubitemid 34828099)
36. Zeng G, Nystrom F H., Ravichandran L V. et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000 101 13 1539-1545 (Pubitemid 30180890)
37. Kamide K, Hori M T., Zhu J H., Barrett J D., Eggena P, Tuck M L. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998 32 3 482-487 (Pubitemid 28429137)
38. Kamide K, Rakugi H, Nagai M et al. Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004 22 1 121-127 (Pubitemid 38293539)
39. Beisswenger P J., Howell S K., Smith K, Szwergold B S. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta 2003 1637 1 98-106 (Pubitemid 36071602)
40. Thornalley P J. Modification of the glyoxalase system in disease processes and prospects for therapeutic strategies. Biochem Soc Trans 1993 21 2 531-534 (Pubitemid 23167962)
41. Alexander M C., Lomanto M, Nasrin N, Ramaika C. Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through cis-acting DNA sequences. Proc Natl Acad Sci U S A 1988 85 14 5092-5096
42. Morgan P E., Dean R T., Davies M J. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 2002 403 2 259-269 (Pubitemid 34800207)
43. Chang K C., Paek K S., Kim H J., Lee Y S., Yabe-Nishimura C, Seo H G. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 2002 61 5 1184-1191 (Pubitemid 34441784)
44. Vasdev S, Gill V D., Singal P K. Modulation of oxidative stress-induced changes in hypertension and atherosclerosis by antioxidants. Exp Clin Cardiol 2006 11 3 206-216 (Pubitemid 44540865)
45. Zeng J, Davies M J. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 2005 18 8 1232-1241 (Pubitemid 41170247)
46. Collison K S., Parhar R S., Saleh S S. et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002 71 3 433-444
47. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003 25 3-4 283-292 (Pubitemid 38041266)
48. Nagaraj R H., Sarkar P, Mally A, Biemel K M., Lederer M O., Padayatti P S. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 2002 402 1 110-119 (Pubitemid 34848300)
49. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley P J. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003 31 Pt 6 1423-1425 (Pubitemid 38030991)
50. Wautier M P., Chappey O, Corda S, Stern D M., Schmidt A M., Wautier J L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001 280 5 E685-E694
51. Kaplan N. Kaplan's Clinical Hypertension. 9th ed. Philadelphia Lippincott Williams & Wilkins 2006
52. Vasdev S, Gill V. Antioxidants in the treatment of hypertension. Int J Angiol 2005 14 60-73 (Pubitemid 43183956)
53. Wen Y, Killalea S, McGettigan P, Feely J. Lipid peroxidation and antioxidant vitamins C and E in hypertensive patients. Ir J Med Sci 1996 165 3 210-212
54. Nyyssönen K, Parviainen M T., Salonen R, Tuomilehto J, Salonen J T. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997 314 7081 634-638 (Pubitemid 27099877)
55. Ness A R., Khaw K T., Bingham S, Day N E. Vitamin C status and blood pressure. J Hypertens 1996 14 4 503-508 (Pubitemid 26161101)
56. Kashyap M K., Yadav V, Sherawat B S. et al. Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 2005 277 1-2 89-99 (Pubitemid 41236190)
57. Gey K F., Puska P, Jordan P, Moser U K. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991 53 1, Suppl 326S-334S
58. Yochum L A., Folsom A R., Kushi L H. Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am J Clin Nutr 2000 72 2 476-483 (Pubitemid 30620655)
59. Manning R D. Jr, Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003 179 3 243-250 (Pubitemid 37464109)
60. Ambrose J A., Barua R S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004 43 10 1731-1737 (Pubitemid 38622506)
61. Wu D, Cederbaum A I. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003 27 4 277-284 (Pubitemid 40685566)
62. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal P K. Free radicals and the heart. J Pharmacol Toxicol Methods 1993 30 2 55-67 (Pubitemid 23352113)
63. Stadtman T C. Selenium biochemistry. Annu Rev Biochem 1990 59 111-127
64. Park Y S., Koh Y H., Takahashi M et al. Identification of the binding site of methylglyoxal on glutathione peroxidase: methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites Arg 184 and 185. Free Radic Res 2003 37 2 205-211 (Pubitemid 36124347)
65. Wu L, Juurlink B H. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002 39 3 809-814 (Pubitemid 34252881)
66. Farahmand F, Lou H, Singal P K. Oxidative stress in cardiovascular complications in diabetes. In: Pierce G N. Nagano M Zahradka P Dhalla N S. eds. Atheroscleriosis, Hypertension and Diabetes. Boston Kleuver Academic Publishers 2003 427-437
67. Chang T, Wang R, Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 2005 38 2 286-293 (Pubitemid 39656138)
68. Kaplan P, Babusikova E, Lehotsky J, Dobrota D. Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem 2003 248 1-2 41-47 (Pubitemid 36833639)
69. Viner R I., Williams T D., Schöneich C. Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. Biochemistry 1999 38 38 12408-12415
70. Nakashima I, Takeda K, Kawamoto Y, Okuno Y, Kato M, Suzuki H. Redox control of catalytic activities of membrane-associated protein tyrosine kinases. Arch Biochem Biophys 2005 434 1 3-10 (Pubitemid 40040464)
71. Rainwater R, Parks D, Anderson M E., Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995 15 7 3892-3903
72. Liu H, Colavitti R, Rovira I I., Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005 97 10 967-974 (Pubitemid 41668909)
73. Suzuki Y J., Ford G D. Redox regulation of signal transduction in cardiac and smooth muscle. J Mol Cell Cardiol 1999 31 2 345-353 (Pubitemid 29089883)
74. Dargel R. Lipid peroxidationa common pathogenetic mechanism? Exp Toxicol Pathol 1992 44 4 169-181
75. Chakravarti R N., Kirshenbaum L A., Singal P K. Atherosclerosis: its pathophysiology with special reference to lipid peroxidation. J Appl Cardiol 1991 6 91-112
76. Berliner J A., Watson A D. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005 353 1 9-11 (Pubitemid 41007802)
77. Touyz R M., Schiffrin E L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004 122 4 339-352 (Pubitemid 39506592)
78. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003 28 9 509-514 (Pubitemid 38340416)
79. Tabatabaie T, Floyd R A. Susceptibility of glutathione peroxidase and glutathione reductase to oxidative damage and the protective effect of spin trapping agents. Arch Biochem Biophys 1994 314 1 112-119 (Pubitemid 24326720)
80. Túri S, Friedman A, Bereczki C et al. Oxidative stress in juvenile essential hypertension. J Hypertens 2003 21 1 145-152 (Pubitemid 36143519)
81. Kedziora-Kornatowska K, Czuczejko J, Pawluk H et al. The markers of oxidative stress and activity of the antioxidant system in the blood of elderly patients with essential arterial hypertension. Cell Mol Biol Lett 2004 9 4A 635-641 (Pubitemid 40065189)
82. Russo C, Olivieri O, Girelli D et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 1998 16 9 1267-1271 (Pubitemid 28408409)
83. Chen P F., Tsai A L., Wu K K. Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem 1994 269 40 25062-25066 (Pubitemid 24311775)
84. Xia Y, Tsai A L., Berka V, Zweier J L. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998 273 40 25804-25808
85. Landmesser U, Dikalov S, Price S R. et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003 111 8 1201-1209 (Pubitemid 36519937)
86. Shinozaki K, Kashiwagi A, Masada M, Okamura T. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 2004 4 1 1-11 (Pubitemid 38404711)
87. Ma X L., Gao F, Nelson A H. et al. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001 298 3 879-885 (Pubitemid 32761899)
88. Touyz R M. Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens 2003 12 2 165-174 (Pubitemid 36288317)
89. Ikemoto F, Song G, Tominaga M, Yamamoto K. Oxidation-induced increase in activity of angiotensin converting enzyme in the rat kidney. Biochem Biophys Res Commun 1988 153 3 1032-1037
90. Griendling K K., Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000 86 5 494-501 (Pubitemid 30165039)
91. Fortuño A, Oliván S, Beloqui O et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004 22 11 2169-2175 (Pubitemid 39463811)
92. Schulman I H., Zhou M S., Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl 2006 24 1 S45-S50 (Pubitemid 44336823)
93. Zaidi N F., Lagenaur C F., Abramson J J., Pessah I, Salama G. Reactive disulfides trigger Ca2+ release from sarcoplasmic reticulum via an oxidation reaction. J Biol Chem 1989 264 36 21725-21736 (Pubitemid 20028742)
94. Tabet F, Savoia C, Schiffrin E L., Touyz R M. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004 44 2 200-208 (Pubitemid 38982163)
95. Suzuki Y J., Ford G D. Inhibition of Ca(2+)-ATPase of vascular smooth muscle sarcoplasmic reticulum by reactive oxygen intermediates. Am J Physiol 1991 261 2 Pt 2 H568-H574
96. Gordeeva A V., Zvyagilskaya R A., Labas Y A. Cross-talk between reactive oxygen species and calcium in living cells. Biochemistry (Mosc) 2003 68 10 1077-1080
97. Mehta P K., Griendling K K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007 292 1 C82-C97 (Pubitemid 46127306)
98. Griendling K K., Minieri C A., Ollerenshaw J D., Alexander R W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994 74 6 1141-1148 (Pubitemid 24176909)
99. Pueyo M E., Gonzalez W, Nicoletti A, Savoie F, Arnal J F., Michel J B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000 20 3 645-651 (Pubitemid 30151676)
100. Hoch N E., Guzik T J., Chen W et al. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 2009 296 2 R208-R216
101. Jurewicz M, McDermott D H., Sechler J M. et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007 18 4 1093-1102 (Pubitemid 46536895)
102. Nataraj C, Oliverio M I., Mannon R B. et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999 104 12 1693-1701 (Pubitemid 30053186)
103. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 2004 43 2 154-155 (Pubitemid 38174166)
104. Daniels S R., Arnett D K., Eckel R H. et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005 111 15 1999-2012 (Pubitemid 40570221)
105. Michel M C., Brodde O E., Insel P A. Peripheral adrenergic receptors in hypertension. Hypertension 1990 16 2 107-120 (Pubitemid 20230834)
106. Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation. Pathogenesis of hypertension and therapeutic aspects. Circ J 2010 74 5 827-835
107. Zhang Z H., Wei S G., Francis J, Felder R B. Cardiovascular and renal sympathetic activation by blood-borne TNF- in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003 284 4 R916-R927 (Pubitemid 36406849)
108. Fuchs B A., Albright J W., Albright J F. -adrenergic receptors on murine lymphocytes: density varies with cell maturity and lymphocyte subtype and is decreased after antigen administration. Cell Immunol 1988 114 2 231-245
109. Petitto J M., Huang Z, McCarthy D B. Molecular cloning of NPY-Y1 receptor cDNA from rat splenic lymphocytes: evidence of low levels of mRNA expression and [125I]NPY binding sites. J Neuroimmunol 1994 54 1-2 81-86
110. Ricci A, Bronzetti E, Conterno A et al. 1-adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension 1999 33 2 708-712 (Pubitemid 29091653)
111. Schmid-Schönbein G W., Seiffge D, DeLano F A., Shen K, Zweifach B W. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 1991 17 3 323-330
112. Arndt H, Smith C W., Granger D N. Leukocyte-endothelial cell adhesion in spontaneously hypertensive and normotensive rats. Hypertension 1993 21 5 667-673 (Pubitemid 23120222)
113. Rodriguez-Iturbe B, Zhan C D., Quiroz Y, Sindhu R K., Vaziri N D. Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 2003 41 2 341-346 (Pubitemid 36204912)
114. Guzik T J., Hoch N E., Brown K A. et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007 204 10 2449-2460 (Pubitemid 47529329)
115. Bataillard A, Blanc-Brunat N, Vivier G et al. Antihypertensive effect of thymectomy in Lyon hypertensive rats. Vascular reactivity, renal histology, and sodium excretion. Am J Hypertens 1996 9 2 171-177 (Pubitemid 26108118)
116. Hilgers K F. Monocytes/macrophages in hypertension. J Hypertens 2002 20 4 593-596 (Pubitemid 34913696)
117. Capers Q IV, Alexander R W., Lou P P. et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997 30 6 1397-1402 (Pubitemid 27528081)
118. Chen X L., Tummala P E., Olbrych M T., Alexander R W., Medford R M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998 83 9 952-959 (Pubitemid 28503085)
119. Rodríguez-Iturbe B, Quiroz Y, Nava M et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002 282 2 F191-F201 (Pubitemid 34654549)
120. Tian N, Gu J W., Jordan S, Rose R A., Hughson M D., Manning R D. Jr. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007 292 2 H1018-H1025
121. Rodríguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri N D. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 2005 68 3 1041-1047 (Pubitemid 43246420)
122. Mattson D L., James L, Berdan E A., Meister C J. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2006 48 1 149-156 (Pubitemid 44297537)
123. Quiroz Y, Pons H, Gordon K L. et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001 281 1 F38-F47
124. Rodríguez-Iturbe B, Pons H, Quiroz Y et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 2001 59 6 2222-2232 (Pubitemid 32467615)
125. Boesen E I., Williams D L., Pollock J S., Pollock D M. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol 2010 37 10 1016-1022
126. Franco M, Martínez F, Rodríguez-Iturbe B et al. Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitive hypertension. Am J Physiol Renal Physiol 2006 291 6 F1281-F1287 (Pubitemid 44887241)
127. Cirillo P, Sautin Y Y., Kanellis J et al. Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant 2009 24 5 1384-1387
128. Glushakova O, Kosugi T, Roncal C et al. Fructose induces the inflammatory molecule ICAM-1 in endothelial cells. J Am Soc Nephrol 2008 19 9 1712-1720
129. Gersch M S., Mu W, Cirillo P et al. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 2007 293 4 F1256-F1261 (Pubitemid 47583960)
130. Mattioli L F., Holloway N B., Thomas J H., Wood J G. Fructose, but not dextrose, induces leukocyte adherence to the mesenteric venule of the rat by oxidative stress. Pediatr Res 2010 67 4 352-356
131. Tan H W., Xing S S., Bi X P. et al. Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. Acta Pharmacol Sin 2008 29 9 1051-1059
132. Nyby M D., Abedi K, Smutko V, Eslami P, Tuck M L. Vascular Angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. Hypertens Res 2007 30 5 451-457 (Pubitemid 46964286)
133. Kokkola R, Andersson A, Mullins G et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005 61 1 1-9 (Pubitemid 40188342)
134. Nagai N, Oike Y, Izumi-Nagai K et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006 26 10 2252-2259 (Pubitemid 44465719)
135. 1 receptor structure-activity correlations in the light of rhodopsin structure. Physiol Rev 2007 87 2 565-592 (Pubitemid 47086283)
136. Ramasamy R, Yan S F., Schmidt A M. RAGE: therapeutic target and biomarker of the inflammatory responsethe evidence mounts. J Leukoc Biol 2009 86 3 505-512
137. Niskanen L, Laaksonen D E., Nyyssönen K et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004 44 6 859-865 (Pubitemid 39577412)
138. Sesso H D., Wang L, Buring J E., Ridker P M., Gaziano J M. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007 49 2 304-310 (Pubitemid 46150768)
139. Zhang Y, Thompson A M., Tong W et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China. J Hypertens 2010 28 1 35-40
140. Dörffel Y, Lätsch C, Stuhlmüller B et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999 34 1 113-117 (Pubitemid 29325728)
141. Wirtz P H., von Känel R, Frey K, Ehlert U, Fischer J E. Glucocorticoid sensitivity of circulating monocytes in essential hypertension. Am J Hypertens 2004 17 6 489-494 (Pubitemid 38726162)
142. Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004 110 9 1103-1107 (Pubitemid 39319009)
143. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003 26 9 691-697 (Pubitemid 37258655)
144. Koh K K., Quon M J., Han S H., Chung W J., Lee Y, Shin E K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006 108 1 96-100 (Pubitemid 43324913)
145. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005 46 6 735-739 (Pubitemid 44378243)
146. Ishimitsu T, Numabe A, Masuda T et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009 32 11 962-968
147. Vanhala M, Kautiainen H, Kumpusalo E. Proinflammation and hypertension: a population-based study. Mediators Inflamm 2008 2008 619704
148. Larrousse M, Bragulat E, Segarra M, Sierra C, Coca A, de La Sierra A. Increased levels of atherosclerosis markers in salt-sensitive hypertension. Am J Hypertens 2006 19 1 87-93 (Pubitemid 43217040)
149. Tappy L, Lê K A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010 90 1 23-46
150. Choi M E. The not-so-sweet side of fructose. J Am Soc Nephrol 2009 20 3 457-459
151. Cirillo P, Gersch M S., Mu W et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 2009 20 3 545-553
152. O'Brien P J., Siraki A G., Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005 35 7 609-662 (Pubitemid 41693601)
153. Madhur M S., Lob H E., McCann L A. et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010 55 2 500-507
154. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008 54 6 945-955 (Pubitemid 351793400)
155. Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007 27 1 84-91 (Pubitemid 46370478)
156. Shi H, Kokoeva M V., Inouye K, Tzameli I, Yin H, Flier J S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006 116 11 3015-3025 (Pubitemid 44684486)
157. Itani S I., Ruderman N B., Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB- Diabetes 2002 51 7 2005-2011 (Pubitemid 34729001)
158. Ellis B A., Poynten A, Lowy A J. et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 2000 279 3 E554-E560
159. Cai D, Yuan M, Frantz D F. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK- and NF-kappaB. Nat Med 2005 11 2 183-190 (Pubitemid 40321354)
160. Poggi M, Bastelica D, Gual P et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007 50 6 1267-1276 (Pubitemid 46701560)
161. Kim F, Pham M, Luttrell I et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007 100 11 1589-1596 (Pubitemid 46897262)
162. Geiger H, Fierlbeck W, Mai M et al. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 1997 51 3 750-761 (Pubitemid 27157959)
163. Harrison D G., Guzik T J., Lob H E. et al. Inflammation, immunity, and hypertension. Hypertension 2011 57 2 132-140
164. Brasier A R., Recinos A III, Eledrisi M S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002 22 8 1257-1266 (Pubitemid 34875734)
165. Sekiguchi K, Li X, Coker M et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 2004 63 3 433-442 (Pubitemid 38970187)
166. Beg M, Gupta A, Khanna V N. Oxidative stress in essential hypertension and role of antioxidants. JIACM 2010 11 287-293
167. Volpe E, Servant N, Zollinger R et al. A critical function for transforming growth factor-, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008 9 6 650-657 (Pubitemid 351712635)
168. Platten M, Youssef S, Hur E M. et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009 106 35 14948-14953
169. Schmitz D, Wilsenack K, Lendemanns S, Schedlowski M, Oberbeck R. -Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation 2007 72 2 286-294 (Pubitemid 46073346)
170. Wang J, Li J, Sheng X et al. -adrenoceptor mediated surgery-induced production of pro-inflammatory cytokines in rat microglia cells. J Neuroimmunol 2010 223 1-2 77-83
171. Agarwal D, Haque M, Sriramula S, Mariappan N, Pariaut R, Francis J. Role of proinflammatory cytokines and redox homeostasis in exercise-induced delayed progression of hypertension in spontaneously hypertensive rats. Hypertension 2009 54 6 1393-1400
172. Tian N, Moore R S., Braddy S et al. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007 293 6 H3388-H3395 (Pubitemid 350230880)
173. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990 85 3 731-738 (Pubitemid 20087475)
174. Ikeda U, Ikeda M, Oohara T et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991 260 5 Pt 2 H1713-H1717
175. Amrani Y, Bronner C. Tumor necrosis factor alpha potentiates the increase in cytosolic free calcium induced by bradykinin in guinea-pig tracheal smooth muscle cells. C R Acad Sci III 1993 316 12 1489-1494 (Pubitemid 24044694)
176. Lazaar A L., Amrani Y, Hsu J et al. CD40-mediated signal transduction in human airway smooth muscle. J Immunol 1998 161 6 3120-3127 (Pubitemid 28425740)
177. Ducreux S, Zorzato F, Müller C et al. Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem 2004 279 42 43838-43846 (Pubitemid 39390690)
178. Rask-Madsen C, Domínguez H, Ihlemann N, Hermann T, Køber L, Torp-Pedersen C. Tumor necrosis factor- inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 2003 108 15 1815-1821 (Pubitemid 37296090)
179. Valerio A, Cardile A, Cozzi V et al. TNF- downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006 116 10 2791-2798 (Pubitemid 44511642)
180. Moller D E. Potential role of TNF- in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000 11 6 212-217 (Pubitemid 30603166)
181. Hotamisligil G S. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003 27 Suppl 3 S53-S55 (Pubitemid 38019190)
182. Sabio G, Das M, Mora A et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008 322 5907 1539-1543
183. Senn J J., Klover P J., Nowak I A. et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003 278 16 13740-13746 (Pubitemid 36799910)
184. Torisu T, Sato N, Yoshiga D et al. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007 12 2 143-154 (Pubitemid 46152654)
185. Emanuelli B, Peraldi P, Filloux C et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor- in the adipose tissue of obese mice. J Biol Chem 2001 276 51 47944-47949
186. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000 275 21 15985-15991 (Pubitemid 30366903)
187. Klover P J., Zimmers T A., Koniaris L G., Mooney R A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003 52 11 2784-2789 (Pubitemid 37339708)
188. Saura M, Zaragoza C, Bao C, Herranz B, Rodriguez-Puyol M, Lowenstein C J. Stat3 mediates interleukin-6 inhibition of human endothelial nitric-oxide synthase expression. J Biol Chem 2006 281 40 30057-30062 (Pubitemid 44537013)
189. Andreozzi F, Laratta E, Procopio C et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 2007 27 6 2372-2383 (Pubitemid 46418488)
190. Hung M J., Cherng W J., Hung M Y., Wu H T., Pang J HS. Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J Hypertens 2010 28 5 940-951
191. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti J F. Interleukin-1-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007 148 1 241-251 (Pubitemid 46021456)
192. Brasier A R., Li J, Wimbish K A. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996 27 4 1009-1017 (Pubitemid 26113850)
193. Cowling R T., Zhang X, Reese V C. et al. Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005 289 3 H1176-H1183 (Pubitemid 41208961)
194. Takeshita Y, Takamura T, Ando H et al. Cross talk of tumor necrosis factor- and the renin-angiotensin system in tumor necrosis factor - induced plasminogen activator inhibitor-1 production from hepatocytes. Eur J Pharmacol 2008 579 1-3 426-432
195. Wassmann S, Stumpf M, Strehlow K et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004 94 4 534-541 (Pubitemid 38326289)
196. Lee D L., Sturgis L C., Labazi H et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 2006 290 3 H935-H940
197. Madhur M S., Lob H E., McCann L A. et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010 55 2 500-507
198. Basuroy S, Bhattacharya S, Tcheranova D et al. HO-2 provides endogenous protection against oxidative stress and apoptosis caused by TNF- in cerebral vascular endothelial cells. Am J Physiol Cell Physiol 2006 291 5 C897-C908 (Pubitemid 44771809)
199. Eringa E C., Stehouwer C DA, Walburg K et al. Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor- dependence on c-Jun N-terminal kinase. Arterioscler Thromb Vasc Biol 2006 26 2 274-280 (Pubitemid 43732187)
200. Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: role of TNF and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009 29 8 1164-1171
201. Heo S K., Yun H J., Park W H., Park S D. Emodin inhibits TNF - induced human aortic smooth-muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis. J Cell Biochem 2008 105 1 70-80
202. Chamberlain J, Francis S, Brookes Z et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS ONE 2009 4 4 e5073
203. Papanicolaou D A., Petrides J S., Tsigos C et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996 271 3 Pt 1 E601-E605
204. Torpy D J., Papanicolaou D A., Lotsikas A J., Wilder R L., Chrousos G P., Pillemer S R. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000 43 4 872-880
205. Gwosdow A R. Mechanisms of interleukin-1-induced hormone secretion from the rat adrenal gland. Endocr Res 1995 21 1-2 25-37
206. Zhang Z H., Wei S G., Francis J, Felder R B. Cardiovascular and renal sympathetic activation by blood-borne TNF- in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003 284 4 R916-R927 (Pubitemid 36406849)
207. Lopez-Garcia E, Schulze M B., Fung T T. et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004 80 4 1029-1035
208. Holt E M., Steffen L M., Moran A et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. J Am Diet Assoc 2009 109 3 414-421
209. Genkinger J M., Platz E A., Hoffman S C., Comstock G W., Helzlsouer K J. Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. Am J Epidemiol 2004 160 12 1223-1233 (Pubitemid 39628063)
210. Guadagni M, Biolo G. Effects of inflammation and/or inactivity on the need for dietary protein. Curr Opin Clin Nutr Metab Care 2009 12 6 617-622
211. Casas-Agustench P, Bulló M, Salas-Salvadó J. Nuts, inflammation and insulin resistance. Asia Pac J Clin Nutr 2010 19 1 124-130
212. Ros E. Nuts and novel biomarkers of cardiovascular disease. Am J Clin Nutr 2009 89 5 1649S-1656S
213. King D E., Egan B M., Woolson R F., Mainous A G. III, Al-Solaiman Y, Jesri A. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch Intern Med 2007 167 5 502-506 (Pubitemid 46425664)
214. Shen J, Lai C Q., Mattei J, Ordovas J M., Tucker K L. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. Am J Clin Nutr 2010 91 2 337-342
215. Morris M S., Sakakeeny L, Jacques P F., Picciano M F., Selhub J. Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. J Nutr 2010 140 1 103-110
216. Scheurig A C., Thorand B, Fischer B, Heier M, Koenig W. Association between the intake of vitamins and trace elements from supplements and C-reactive protein: results of the MONICA/KORA Augsburg study. Eur J Clin Nutr 2008 62 1 127-137
217. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005 25 151-174 (Pubitemid 41208998)
218. Devaraj S, Leonard S, Traber M G., Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med 2008 44 6 1203-1208
219. Wu S J., Liu P L., Ng L T. Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Mol Nutr Food Res 2008 52 8 921-929
220. Wannamethee S G., Lowe G DO, Rumley A, Bruckdorfer K R., Whincup P H. Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr 2006 83 3 567-574 quiz 726-727 (Pubitemid 44699201)
221. Helmersson J, Arnlöv J, Larsson A, Basu S. Low dietary intake of -carotene, -tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort. Br J Nutr 2009 101 12 1775-1782
222. Aguirre R, May J M. Inflammation in the vascular bed: importance of vitamin C. Pharmacol Ther 2008 119 1 96-103
223. Chang H H., Chen C S., Lin J Y. High dose vitamin C supplementation increases the Th1/Th2 cytokine secretion ratio, but decreases eosinophilic infiltration in bronchoalveolar lavage fluid of ovalbumin-sensitized and challenged mice. J Agric Food Chem 2009 57 21 10471-10476
224. Jain S K., Velusamy T, Croad J L., Rains J L., Bull R. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats. Free Radic Biol Med 2009 46 12 1633-1638
225. Tsai G Y., Cui J Z., Syed H et al. Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats. Clin Experiment Ophthalmol 2009 37 2 223-231
226. Kim C J., Kovacs-Nolan J, Yang C, Archbold T, Fan M Z., Mine Y. L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim Biophys Acta 2009 1790 10 1161-1169
227. Csontos C, Rezman B, Foldi V et al. Effect of N-acetylcysteine treatment on the expression of leukocyte surface markers after burn injury. Burns 2011 37 3 453-464
228. Marracci G H., Jones R E., McKeon G P., Bourdette D N. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002 131 1-2 104-114
229. Morini M, Roccatagliata L, Dell'Eva R et al. -lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004 148 1-2 146-153 (Pubitemid 38229567)
230. Schreibelt G, Musters R JP, Reijerkerk A et al. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol 2006 177 4 2630-2637 (Pubitemid 44201022)
231. Chaudhary P, Marracci G H., Bourdette D N. Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006 175 1-2 87-96
232. Yadav V, Marracci G, Lovera J et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005 11 2 159-165 (Pubitemid 40403253)
233. Salinthone S, Yadav V, Schillace R V., Bourdette D N., Carr D W. Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. PLoS ONE 2010 5 9 1-10
234. ehirli AÖ, Tatlidede E, Yüksel M et al. Protective effects of alpha-lipoic acid against oxidative injury in TNBS-induced colitis. Erciyes Tip Dergisi 2009 31 15-26
235. Appel L J., Moore T J., Obarzanek E et al, DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997 336 16 1117-1124
236. Sacks F M., Svetkey L P., Vollmer W M. et al, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001 344 1 3-10 (Pubitemid 32064838)
237. Martin D W., Mayes P A., Rodwell V W. Harper's Review of Biochemistry. 19th ed. Los Altos, CA Lange Medical Publications 1983 22 101-105 120 183-184 187-188 597-599
238. Tsuchiya Y, Yamaguchi M, Chikuma T, Hojo H. Degradation of glyceraldehyde-3-phosphate dehydrogenase triggered by 4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal. Arch Biochem Biophys 2005 438 2 217-222 (Pubitemid 40798021)
239. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Des 2003 9 29 2385-2402 (Pubitemid 37236360)
240. Stocker R, Keaney J F. Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004 84 4 1381-1478 (Pubitemid 39302636)
241. Dickhout J G., Hossain G S., Pozza L M., Zhou J, Lhoták S, Austin R C. Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: implications in atherogenesis. Arterioscler Thromb Vasc Biol 2005 25 12 2623-2629 (Pubitemid 43732288)
242. Guzik T J., Sadowski J, Guzik B et al. Coronary artery superoxide production and NOX isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 2006 26 2 333-339 (Pubitemid 43732196)
243. Li W G., Miller F J. Jr, Zhang H J., Spitz D R., Oberley L W., Weintraub N L. H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 2001 276 31 29251-29256 (Pubitemid 37452016)
244. Jiang F, Drummond G R., Dusting G J. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 2004 11 2 79-88 (Pubitemid 39207181)
245. Dixon L J., Hughes S M., Rooney K et al. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens 2005 18 6 839-843 (Pubitemid 40745271)
246. Bartlett R K., Bieber Urbauer R J., Anbanandam A, Smallwood H S., Urbauer J L., Squier T C. Oxidation of Met144 and Met145 in calmodulin blocks calmodulin dependent activation of the plasma membrane Ca-ATPase. Biochemistry 2003 42 11 3231-3238 (Pubitemid 36348631)
247. Biswas S K., de Faria J B. Which comes first: renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res 2007 41 2 216-224 (Pubitemid 46992872)
248. Franco M, Martínez F, Quiroz Y et al. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 2007 293 1 R251-R256 (Pubitemid 47096573)
249. Crowley S D., Frey C W., Gould S K. et al. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008 295 2 F515-F524
250. Peeters ACTM, Netea M G., Janssen M C., Kullberg B J., Van der Meer J W., Thien T. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 2001 31 1 31-36 (Pubitemid 32151119)
251. Sela S, Shurtz-Swirski R, Farah R et al. A link between polymorphonuclear leukocyte intracellular calcium, plasma insulin, and essential hypertension. Am J Hypertens 2002 15 4 Pt 1 291-295 (Pubitemid 34408966)
252. Lakoski S G., Herrington D M., Siscovick D M., Hulley S B. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006 166 3 345-349 (Pubitemid 43244323)
253. Antonelli A, Fallahi P, Rotondi M et al. High serum levels of CXC chemokine ligand 10 in untreated essential hypertension. J Hum Hypertens 2008 22 8 579-581